In this setting, radionuclide therapy targeting the prostate-membrane-specific antigen (PSMA), a class II membrane glycoprotein frequently overexpressed by prostate cancer cells [2], is a promising palliative treatment option. Here, FOLH1 is linked to prostate cancer.